 |
Vol.60 No.5 contents | Japanese/English |
 | Full Text of PDF (1162K) Article in Japanese |
- Case Report -
An Elderly Case of Lung Adenocarcinoma with an Epidermal Growth Factor Receptor Gene L861Q Mutation Which Was Successfully Treated with Osimertinib
Yasutaka Kato1, Toshio Kato1, Hiroyuki Tanaka1, Shigehisa Kajikawa1, Toshiyuki Yonezawa1, Yuki Yamamoto2, Toyonori Tsuzuki2, Etsuro Yamaguchi1, Akihito Kubo1, Satoru Ito11Department of Respiratory Medicine and Allergology, 2Department of Surgical Pathology, Aichi Medical University, Japan
Background. The clinical efficacy of osimertinib in non-small-cell lung cancer (NSCLC) with uncommon epidermal growth factor receptor (EGFR) mutations remains unclear. The efficacy and safety of osimertinib in elderly patients with these mutations have not been established. We herein report an elderly case of lung adenocarcinoma with an uncommon EGFR mutation treated successfully with osimertinib. Case. An 84-year-old female presented with a chest abnormal shadow after a medical health checkup. Computed tomography revealed a tumor in the left upper lobe and enlargement of mediastinal lymph nodes. She was found to have multiple brain and bone metastases. She was diagnosed with stage IVB pulmonary adenocarcinoma (cT4N3M1c), harboring an EGFR L861Q gene mutation. She received 80 mg/day of osimertinib, and then the dose was reduced to 40 mg/day due to appetite loss. The tumor responded well to osimertinib, resulting in a partial response. The dose of osimertinib was returned to 80 mg/day after re-elevation of CEA, but she experienced no severe adverse events. She has been treated with the same dose of osimertinib without disease progression or severe adverse events. Conclusion. Osimertinib was effective and well-tolerated in an elderly patient with lung adenocarcinoma harboring the EGFR L861Q mutation.
key words: Epidermal growth factor receptor, Mutation, Osimertinib, Uncommon mutation, L861Q
Received: May 28, 2020
Accepted: June 24, 2020
JJLC 60 (5): 411-415, 2020
